TGF-β1 and other factors such as tumor-secreted exosomes41 and germline mutations3 may be used clinically to identify people at high risk for glioma, identify cases before symptoms occur, and identify patients with tumors responsive to anti-TGF-β therapy. Here, TGFB1 is linked to central nervous system cancer.